Vertex Pharmaceuticals Incorporated
VRTX
$493.84
$1.370.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.02B | 10.63B | 10.34B | 10.19B | 9.87B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.02B | 10.63B | 10.34B | 10.19B | 9.87B |
| Cost of Revenue | 5.00B | 4.93B | 4.79B | 4.55B | 4.43B |
| Gross Profit | 6.02B | 5.69B | 5.55B | 5.64B | 5.44B |
| SG&A Expenses | 1.43B | 1.46B | 1.35B | 1.24B | 1.14B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.43B | 6.39B | 6.14B | 5.79B | 5.56B |
| Operating Income | 4.59B | 4.24B | 4.20B | 4.40B | 4.31B |
| Income Before Tax | 248.50M | 259.60M | 214.70M | 4.77B | 4.38B |
| Income Tax Expenses | 784.10M | 739.40M | 704.60M | 748.00M | 760.20M |
| Earnings from Continuing Operations | -535.60 | -479.80 | -489.90 | 4.02K | 3.62K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -535.60M | -479.80M | -489.90M | 4.02B | 3.62B |
| EBIT | 4.59B | 4.24B | 4.20B | 4.40B | 4.31B |
| EBITDA | 4.77B | 4.45B | 4.39B | 4.58B | 4.48B |
| EPS Basic | -2.07 | -1.85 | -1.89 | 15.58 | 14.04 |
| Normalized Basic EPS | 12.32 | 11.58 | 11.59 | 12.05 | 11.75 |
| EPS Diluted | -2.20 | -2.00 | -2.04 | 15.41 | 13.89 |
| Normalized Diluted EPS | 12.21 | 11.48 | 11.49 | 11.92 | 11.63 |
| Average Basic Shares Outstanding | 1.03B | 1.03B | 1.03B | 1.03B | 1.03B |
| Average Diluted Shares Outstanding | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |